About Amunix
Amunix is a company based in Mountain View (United States) founded in 2006 was acquired by Sanofi in December 2021. Amunix has raised $200.59 million across 9 funding rounds from investors including BlackRock, Bain Capital and Franklin Templeton. The company has 82 employees as of December 31, 2021. Amunix operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Biogen, among others.
- Headquarter Mountain View, United States
- Employees 82 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Amunix Operating Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Amunix
Unlock access to complete
Funding Insights of Amunix
Amunix has successfully raised a total of $200.59M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $117 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Amunix
Amunix has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include BlackRock, Bain Capital and Franklin Templeton.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private investment firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Debt and equity investments are pursued across multiple sectors.
|
Locked | Locked | Locked | |
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked |
Investor details for Amunix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Amunix
Investment portfolio details for Amunix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Amunix
Detailed financials for Amunix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Amunix Comparisons
Peer comparison for Amunix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Amunix
Amunix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Biogen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
Detailed competitors of Amunix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Amunix
Complete news archive for Amunix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Amunix
Amunix was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Amunix is headquartered in Mountain View, United States. It is registered at Mountain View, California, United States.
Amunix is a funded company, having raised a total of $200.59M across 9 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Amunix is 82.
Developer of peptide-based therapeutics. The lead candidate AMX-818 is a masked T cell engager targeting HER2, a receptor tyrosine kinase expressed on a wide variety of solid tumors, others include Wave2 XPAT, Wve3 XPAT, IL12 XPAC, and others for immune disorders and cancers. The companys products are based on its proprietary XTEN half-life extension, XDC drug-conjugate delivery, and ProTIA pro-drug, bispecific T cell engager platform.
Amunix's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Amunix has 19 investors. Key investors include BlackRock, Bain Capital, Franklin Templeton, Sanofi, and HHS.